Loading provider…
Loading provider…
Gynecologic Oncology Physician in Philadelphia, PA
NPI: 1235164104Primary Practice Location
TEMPLE UNIVERSITY HOSPITAL
100 E Lehigh Ave, Philadelphia, PA
Primary Employer
Temple Faculty GYN/Oncology Associates
foxchase.org
HQ Phone
Get MD Stephen's Phone NumberMobile
Get MD Stephen's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 104 | 113 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 68 | 91 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 47 | 112 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 31 | 31 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 14 | 14 |
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Authors: Sharon Diamond
Journal: Cancer Discov
Authors: Myers Virtue, Shannon, Manne, Sharon L, Ozga, Melissa, Kissane, David W, Rubin, Stephen, Heckman, Carolyn, Rosenblum, Norm, Graff, John J
Journal: Int J Gynecol Cancer
Authors: Nestor Esnaola, Alan Haber, Sanjay Reddy, Alexander Kutikov, David Chen, Jeffrey Farma, Robert Uzzo, Rosalia Viterbo, Jason Castellanos, Ariella Altman, Sameer Patel, Christina Chu, Marc Smaldone, Kenneth Patrick, John Ridge, Raju Chelluri
Journal: Ann Surg
Publication Date: 2024-07-24
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: DRUG: Carboplatin, DRUG: Docetaxel, OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Bevacizumab, DRUG: Gemcitabine Hydrochloride, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel